SPY295.44+0.56 0.19%
DIA244.88-0.14 -0.06%
IXIC9,324.59+39.71 0.43%

RBC Capital Upgrades Sage Therapeutics to Outperform, Lowers Price Target to $60

RBC Capital analyst Brian Abrahams upgrades Sage Therapeutics (NASDAQ:SAGE) from Sector Perform to Outperform and lowers the price target from $73 to $60.

Benzinga · 03/18/2020 10:28

RBC Capital analyst Brian Abrahams upgrades Sage Therapeutics (NASDAQ:SAGE) from Sector Perform to Outperform and lowers the price target from $73 to $60.